Tags

Type your tag names separated by a space and hit enter

Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
Climacteric 2002; 5(2):151-5C

Abstract

OBJECTIVE

To determine the risk of recurrence of breast cancer associated with the use of hormone replacement therapy (HRT) in the management of menopausal symptoms in women previously treated for breast cancer who were taking concurrent tamoxifen or who were estrogen receptor-positive.

METHODS

The study group comprised 1472 women with histologically confirmed breast cancer, of whom 342 subjects (23.2%) elected to use hormonal therapy in the management of their menopausal symptoms. Women were not excluded from treatment with hormonal therapy if they were taking adjuvant tamoxifen or if they had receptor-positive breast cancer. The response of these patients was compared with that of the rest of the database. A Cox regression analysis was performed with sex hormone usage as time-dependent covariate. Disease-free interval was the outcome measured.

RESULTS

Subjects who took concurrent tamoxifen with combined continuous estrogen-progestogen therapy had a hazard ratio of 0.67 (95% confidence interval (CI) 0.14-3.24, p = 0.62), while concurrent tamoxifen and topical vaginal estrogen users had a hazard ratio of 0.31 (95% CI 0.10-2.57, p = 0.28). The hazard ratio for the estrogen-progestogen users who were estrogen receptor-positive was 0.24 (95% CI 0.10-1.49, p = 0.14).

CONCLUSIONS

The use of HRT was not associated with an increased risk of recurrence of breast cancer in women taking concurrent tamoxifen or who were estrogen receptor-positive.

Authors+Show Affiliations

School of Women's and Children's Health, University of New South Wales, Royal Hospital for Women, Randwick, Australia.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12051110

Citation

Dew, J E., et al. "Tamoxifen, Hormone Receptors and Hormone Replacement Therapy in Women Previously Treated for Breast Cancer: a Cohort Study." Climacteric : the Journal of the International Menopause Society, vol. 5, no. 2, 2002, pp. 151-5.
Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. Climacteric. 2002;5(2):151-5.
Dew, J. E., Wren, B. G., & Eden, J. A. (2002). Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. Climacteric : the Journal of the International Menopause Society, 5(2), pp. 151-5.
Dew JE, Wren BG, Eden JA. Tamoxifen, Hormone Receptors and Hormone Replacement Therapy in Women Previously Treated for Breast Cancer: a Cohort Study. Climacteric. 2002;5(2):151-5. PubMed PMID: 12051110.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. AU - Dew,J E, AU - Wren,B G, AU - Eden,J A, PY - 2002/6/8/pubmed PY - 2002/11/26/medline PY - 2002/6/8/entrez SP - 151 EP - 5 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric VL - 5 IS - 2 N2 - OBJECTIVE: To determine the risk of recurrence of breast cancer associated with the use of hormone replacement therapy (HRT) in the management of menopausal symptoms in women previously treated for breast cancer who were taking concurrent tamoxifen or who were estrogen receptor-positive. METHODS: The study group comprised 1472 women with histologically confirmed breast cancer, of whom 342 subjects (23.2%) elected to use hormonal therapy in the management of their menopausal symptoms. Women were not excluded from treatment with hormonal therapy if they were taking adjuvant tamoxifen or if they had receptor-positive breast cancer. The response of these patients was compared with that of the rest of the database. A Cox regression analysis was performed with sex hormone usage as time-dependent covariate. Disease-free interval was the outcome measured. RESULTS: Subjects who took concurrent tamoxifen with combined continuous estrogen-progestogen therapy had a hazard ratio of 0.67 (95% confidence interval (CI) 0.14-3.24, p = 0.62), while concurrent tamoxifen and topical vaginal estrogen users had a hazard ratio of 0.31 (95% CI 0.10-2.57, p = 0.28). The hazard ratio for the estrogen-progestogen users who were estrogen receptor-positive was 0.24 (95% CI 0.10-1.49, p = 0.14). CONCLUSIONS: The use of HRT was not associated with an increased risk of recurrence of breast cancer in women taking concurrent tamoxifen or who were estrogen receptor-positive. SN - 1369-7137 UR - https://www.unboundmedicine.com/medline/citation/12051110/Tamoxifen_hormone_receptors_and_hormone_replacement_therapy_in_women_previously_treated_for_breast_cancer:_a_cohort_study_ L2 - http://www.diseaseinfosearch.org/result/960 DB - PRIME DP - Unbound Medicine ER -